title: [Pharmaceutical intervention in duration of antimicrobial treatment at hospital ambit].
abstract: OBJECTIVE
  To estimate the acceptance of the pharmaceutical intervention in controlling duration of antimicrobial therapy and to evaluate their impact on optimizing the treatment.
  
  
  METHODS
  Prospective observational study for two years in a General University Hospital. For the patients record, we followed non critical adult patients with antibiotic treatment. When the duration of antimicrobial treatment not complied with established criteria for each antibiotic and pathology, there was a communication with the physician, at which is recommended to assess the need for continue treatment. The acceptance of pharmaceutical intervention was collected and afterwards we analyzed the impact of this work by antimicrobial consumption and incidence of Clostridium difficile.
  
  
  RESULTS
  . In 122 patients the pharmacist made a pharmaceutical intervention due to prolonged antibiotic treatment. The most prevalent antibiotics were β-lactams, specifically meropenem. The intravenous administration was more frequent. In 77 cases it was decided to recommend the suspension of treatment, we conducted an orally prospective intervention at 70.15 % and the rest of interventions were written. Acceptance was 65.95 % and 65.00%, respectively. During the study period, the DDD of the antimicrobials decreased by 8.89% and expenditure on antimicrobials one 40.12%. The incidence of C. difficile was stable.
  
  
  CONCLUSIONS
  . In a hospital, a pharmaceutical counselling program on the duration of antimicrobial therapy is well accepted by the prescriber physician, but it must be improved. The route of information does not affect the degree of acceptance. These actions could involve a reduction of antimicrobial consumption.
authors.affiliation: María Morante Hernández, Servicio de Farmacia, Hospital General Universitario de Elche, Camino de la Almazara, s/n, 03203, Elche (Alicante), Spain. maria.morante@uv.es.
authors.forename: M
authors.initials: M
authors.lastname: Morante
authors.forename: C
authors.initials: C
authors.lastname: Matoses-Chirivella
authors.forename: F J
authors.initials: FJ
authors.lastname: Rodríguez-Lucena
authors.forename: J M
authors.initials: JM
authors.lastname: Del Moral
authors.forename: M
authors.initials: M
authors.lastname: Ruiz-García
authors.forename: A
authors.initials: A
authors.lastname: Navarro-Ruiz
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use*; D016360:Clostridioides difficile; D004363:Drug Utilization / Q000706:statistics & numerical data; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy / Q000453:epidemiology; D006769:Hospitals, General; D006801:Humans; D000077731:Meropenem; D010607:Pharmacy Service, Hospital / Q000706:statistics & numerical data*; D011446:Prospective Studies; D013030:Spain; D013845:Thienamycins / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D013845:Thienamycins; D000077731:Meropenem